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Abstract
The Bacille Calmette Guérin (BCG) vaccine is the only routine vaccination at birth that effec-
tively induces neonatal T-helper 1 (Th1)-polarized immune responses. The primary cyto-
kine that drives CD4+ T-cell Th1 differentiation is interleukin (IL)-12 p70, a heterodimeric
cytokine composed of the IL-12 p35 and IL-12 p40 subunits. We therefore examined the
mechanisms involved in BCG vaccine stimulation of IL-12 p35 and p40 production from
human umbilical cord (neonatal) cells. We found that BCG bacilli did not upregulate IL-12
p35 mRNA production, but upregulated IL-12 p40 mRNA production in a Toll-like receptor
(TLR)2-dependent manner, in human neonatal monocyte-derived dendritic cells (mdDCs).
The combination of TLR2 signaling, Type I interferon (IFN), and Type II IFN induced maxi-
mal levels of IL-12 p35 and p40 mRNA production in human neonatal mdDCs. The cell-free
supernatants of reconstituted BCG vaccine vials contained extracellular mycobacterial
(BCG) DNA which could induce IFN-α (Type I IFN) production in human neonatal plasmacy-
toid dendritic cells (pDCs). BCG bacilli also stimulated human neonatal CD16lo natural killer
(NK) cells to produce IFN-γ (Type II IFN) in a TLR2-dependent manner. We have therefore
proposed a model where BCG vaccine could stimulate the combination of neonatal conven-
tional DCs (cDCs), pDCs, and CD16lo NK cells to produce optimal neonatal IL-12 p35 and
p40 (IL-12 p70) production and subsequent CD4+ T-cell Th1 polarization. An adjuvant that
emulates the mechanism by which the BCG vaccine stimulates neonatal IL-12 p35 and p40
production could improve vaccine strategies at birth for protection against intracellular path-
ogens and toxins.
Introduction
The Bacille Calmette Guérin (BCG) vaccine is given to neonates in most countries to prevent
infantile tuberculous meningitis and miliary disease. It is one of the most widely used vaccines
worldwide. The efficacy of neonatal BCG administration has been linked to its ability to effec-
tively induce anti-mycobacterial CD4+ T-cell T-helper 1 (Th1)-polarized neonatal immune
PLOSONE | DOI:10.1371/journal.pone.0162148 August 29, 2016 1 / 12
a11111
OPEN ACCESS
Citation: Kativhu CL, Libraty DH (2016) A Model to
Explain How the Bacille Calmette Guérin (BCG)
Vaccine Drives Interleukin-12 Production in
Neonates. PLoS ONE 11(8): e0162148. doi:10.1371/
journal.pone.0162148
Editor: Tobias R Kollmann, University of British
Columbia, CANADA
Received: July 25, 2016
Accepted: August 17, 2016
Published: August 29, 2016
Copyright: © 2016 Kativhu, Libraty. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by a grant from
the U.S. National Institutes of Health R01AI091820.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
responses [1–5]. Neonatal BCG vaccination has also been reported to reduce neonatal and
infant mortality due to diseases other than tuberculosis [6–8]. The all-cause mortality benefit
of neonatal BCG vaccination may be partially related to its ability to also induce heterologous
Th1-polarizing immune responses during the neonatal period [9–12]. Th1 responses are char-
acterized by CD4+ T-cell interferon (IFN)-γ production. The primary cytokine that drives
CD4+ T-cell Th1 differentiation is interleukin (IL)-12 p70, a heterodimeric cytokine composed
of the IL-12 p35 and IL-12 p40 subunits [13, 14]. Neonates and infants generally have reduced
IL-12 p70 production and CD4+ T-cell Th1 responses to intracellular pathogens and toxins
[15–18]. The fetal and early neonatal immune system is heavily Th2 and Th17-biased [15, 17,
19, 20]. Enhanced neonatal Th1-polarized immune responses would be beneficial for combat-
ing infections with intracellular pathogens and toxin-producing organisms.
The BCG vaccine is the only routine vaccination that can be given at birth and induce
Th1-polarized immune responses in neonates [1–4]. Previous reports have shown that BCG
vaccination at birth results in neonatal IFN-γ production against mycobacterial antigens [1],
and the levels of secreted IFN-γ are comparable to adult levels [2]. We and others have previ-
ously identified some of the heterologous immune effects of BCG vaccination, including Th1
polarization [5, 10, 11, 21]. IL-12 p70 is the prototypical Th1-polarizing cytokine [14]. We
therefore examined the BCG vaccine stimulation of IL-12 p70 production from human umbili-
cal cord (neonatal) cells by analyzing the induction of each subunit (p35 and p40). We found
that BCG bacilli did not upregulate IL-12 p35 mRNA production, but upregulated IL-12 p40
mRNA production in a Toll-like receptor (TLR)2-dependent manner, in human neonatal
monocyte-derived dendritic cells (mdDCs). IL-12 p35 gene transcription was previously
shown to be repressed in human neonatal mdDCs [22, 23]. Goriely et al. [22] demonstrated
that lipopolysaccharide (LPS) + IFN-γ (Type II IFN) stimulation of neonatal mdDCs was able
to induce IL-12 p35 and p40 mRNA production that approached adult levels. LPS is a TLR4
ligand that stimulates both NF-κB activation and the Type I IFN pathway [24]. We found that
the combination of a synthetic TLR2 agonist (NF-κB activation only), Type I IFN, and Type II
IFN induced the maximal levels of IL-12 p35 and IL-12 p40 mRNA production in human neo-
natal mdDCs. We hypothesized that the BCG vaccine uses the same signaling combination,
utilizing multiple innate immune cells, in order to produce adult-like levels of IL-12 p35 and
p40 (IL-12 p70) in neonates. We found that the cell-free supernatants of reconstituted BCG
vaccine vials contained extracellular mycobacterial (BCG) DNA which could induce IFN-α
(Type I IFN) production in human neonatal plasmacytoid dendritic cells (pDCs). We also
found that BCG bacilli stimulated human neonatal CD16lo natural killer (NK) cells to produce
IFN-γ (Type II IFN) in a TLR2-dependent manner. We have therefore proposed a model
where BCG vaccine could stimulate the combination of neonatal conventional DCs (cDCs),
pDCs, and CD16lo NK cells thereby producing optimal neonatal IL-12 p35 and p40 production
(IL-12 p70) and subsequent CD4+ T-cell Th1 polarization.
Methods
Ethics Statement
Human umbilical cord blood was collected from the full-term placentas of healthy mothers
with uncomplicated deliveries at the University of Massachusetts Memorial Medical Center
Labor and Delivery Ward. The clinical study protocol was approved by the University of Mas-
sachusetts Medical School (UMMS) institutional review board (IRB). Umbilical cord blood
was collected after verbal consent was obtained. Verbal consent was approved by the UMMS
IRB, as obtaining written consent was not feasible on the Labor and Delivery Ward. Subject’s
verbal consent was recorded on a datasheet.
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Drugs, reagents, and antibodies
The recombinant (r) cytokines IL-2, IL-3, IL-4 and GM-CSF were obtained from Peprotech
Inc., and used at final concentrations of 100 U/ml (rIL-2), 1000 U/ml (rIL-3), 100 U/ml (rIL-4)
and 800 U/ml (rGM-CSF). The monoclonal antibodies (mAbs) against human TLR2 (clone
#383936) and the IgG2B isotype control (clone #20116) were obtained from R&D Systems, and
used at a final concentration of 20 μg/ml. Unless otherwise stated, all mAbs for FACS staining
were obtained from BD Biosciences. For cell stimulations (mdDCs, pDCs, and NK cells), the
Tice BCG vaccine (Merck) was reconstituted in sterile water, per the manufacturer’s instruc-
tions, and used at a final concentration of 8x104 colony forming units (cfu)/ml. For the pDC
experiments, the synthetic TLR2 agonist Pam3CSK4 (Invivogen), was used at a concentration
of 300 ng/ml; recombinant human IFN-β (PBL Assay Science) was used at a concentration of
1x104 U/ml; and recombinant human IFN-γ (PBL Assay Science) was used at a concentration
of 1x103 U/ml.
Cells
Cord blood mononuclear cells (CBMC) were isolated by density gradient centrifugation (His-
topaque™, Sigma-Aldrich) and cryopreserved within 24 hours post-delivery. To generate
mdDCs, CBMC CD14+ monocytes were negatively selected by MACS1 using the Monocyte
Isolation kit II (Miltenyi Biotec). The monocytes were then plated in 24-well plates at 1.7x106
cells/well, and cultured in RPMI 1640/10% FCS/rIL-4/rGM-CSF for 7 days. Differentiation
into immature mdDCs (lineage-CD1c+CD83lo) was 70%, as confirmed by flow cytometry.
pDCs were isolated from CBMC by MACS1 negative selection using the Plasmacytoid Den-
dritic Cell Isolation Kit II (Miltenyi Biotec), and cultured in RPMI 1640/10% FCS/rIL-3 (>95%
purity). NK cells were negatively selected by MACS1 using the NK Cell Isolation Kit Human
(Miltenyi Biotec), and cultured in RPMI 1640/10% FCS/rIL-2 (>95% purity).
BCG stimulation of mdDCs
Immature mdDCs were left unstimulated, or stimulated with BCG x 18–24 hours ± pre-incu-
bation for 1 hour with a TLR2 blocking mAb or an isotype control mAb. An approximate mul-
tiplicity of infection (MOI) = 5 was used. The cells were then lysed and cytosolic RNA was
extracted using RNeasy Plus (Qiagen), according to the manufacturer’s instructions. Relative
gene expression for IL-12 p35 and IL-12 p40 mRNA was determined by quantitative (q)RT-
qPCR. GAPDH was used as the housekeeping gene.
BCG DNA stimulation of pDCs
BCG DNA was extracted from a BCG culture (kindly provided by Christopher Sassetti,
UMMS). pDCs were stimulated with 100 μg/ml BCG DNA for 8 hours; cell lysates were col-
lected for IFN-α1 and IFN-α2 gene expression analysis using qRT-PCR. β-actin was used as
the housekeeping gene. In some experiments, pDCs were stimulated with intact BCG bacilli
(Tice strain) in a similar fashion as described for mdDCs. All qRT-qPCR assays were per-
formed using the TaqMan Gene Expression assay system (Applied Biosystems), following the
manufacturer’s instructions. Analysis was performed using ABI 7500 Software v2.0 (Applied
Biosystems).
Identifying extracellular BCG DNA in BCG vaccine vials
BCG vaccine vials were obtained from two different manufacturers- Tice BCG (Pasteur strain)
fromMerck, USA, and Tokyo BCG (Japan strain) from the Japan BCG Laboratory, Japan. The
BCG Vaccine Induction of IL-12 in Neonates
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BCG vaccine vials were reconstituted in sterile water, per the manufacturer’s instructions, and
spun down to collect the cell-free supernatants for PCR. PCR for 2 mycobacterial genes, rpoB
and the RD8 portion in BCG, was performed as described in [25].
Flow cytometry
Cord blood NK cells were isolated by MACS1, and seeded at a density of 1x106 cells/tube. The
cells were stimulated with BCG overnight, incubated with Brefeldin-A (1 μg/ml, Qiagen) for
the last 4 hours, stained with a vital dye (L/D Aqua), fixed and permeabilized (Cytofix/Cyto-
perm, BD Biosciences), and then stained with the mouse anti-human mAbs to CD3 (clone
SK7), CD16 (clone 3G8), CD56 (clone NCAM16.2), and IFN-γ (clone 25723.11). A minimum
of 50,000 events were acquired. To test if IFN-γ production was dependent on TLR2 signaling,
isolated NK cells were pre-incubated for 1 hour with either anti-TLR2 antibody or IgG isotype
control (R&D Systems) prior to stimulation with BCG. Events were acquired on an LSRII flow
cytometer (Becton Dickinson), and analyzed using FlowJo™ v10.1 software (FlowJo LLC).
Statistical analysis
Statistical analysis was done using Prism 7 software (GraphPad Prism 7). Comparisons
between paired groups were made using the non-parametric Wilcoxon's signed-rank test. P-
values< 0.05 were considered significant.
Results
BCG does not induce IL-12 p35 mRNA production, but induces IL-12
p40 mRNA production in a TLR2-dependent manner, from human
neonatal mdDCs
It has been well established that the BCG vaccine is able to produce anti-mycobacterial neona-
tal CD4+ T-cell Th1 responses in vivo [1–5]. The prototypical Th1-polarizing cytokine is IL-12
p70 [14]. IL-12 p70 is a heterodimeric cytokine made up of the p35 and p40 subunits. We
therefore examined BCG stimulation of IL-12 p35 and p40 mRNA production in human neo-
natal mdDCs. Human umbilical cord blood CD14+ monocytes were differentiated into
mdDCs using IL-4 and GM-CSF. We found that BCG stimulation did not upregulate IL-12
p35 mRNA production in human neonatal mdDCs (Fig 1A). However, BCG upregulated IL-12
p40 mRNA production in a TLR2-dependent manner (Fig 1B). The addition of TLR4 blockade
to TLR2 blocking did not further diminish IL-12 p40 mRNA production (data not shown).
The combination of a synthetic TLR2 agonist (Pam3CSK4), rIFN-β
(Type I IFN), and rIFN-γ (Type II IFN) stimulates maximal levels of IL-12
p35 and IL-12 p40 mRNA production in human neonatal mdDCs
Human neonatal mdDCs have repressed IL-12 p35 gene expression compared to adult cells
[22]. The transcriptional repression of IL-12 p35 in human neonatal mdDCs takes place at the
chromatin level [23]. We interpreted data shown by Goriely et al. [22], that LPS + IFN-γ could
increase IL-12 p35 gene expression in human neonatal mdDCs in similar fashion to adult
mdDCs, to mean that a combination of NF-κB activation, Type I IFN signaling, and Type II
IFN priming was needed for optimal neonatal IL-12 p35 production. We therefore primed neo-
natal mdDCs for 12 h with IFN-β and IFN-γ prior to stimulating them with a synthetic TLR2
agonist, Pam3CSK4. We observed that the combination of Pam3CSK4 + rIFN-β + rIFN-γ
induced the maximal levels of IL-12 p35 mRNA (Fig 2A) and IL-12 p40 mRNA production
BCG Vaccine Induction of IL-12 in Neonates
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(Fig 2B) from human neonatal mdDCs, and the mRNA relative expression levels were nor-
mally distributed (SPSS Statistics v24.0).
Fig 1. Bacille Calmette Guérin (BCG) does not induce IL-12 p35mRNA production from human neonatal monocyte-derived dendritic
cells (mdDCs), but induces IL-12 p40mRNA production in a Toll-like receptor (TLR)2-dependent manner.Human umbilical cord blood
CD14+ monocytes were differentiated into mdDCs using rIL-4 and rGM-CSF, stimulated with BCG x 18–24 hours, and then cellular mRNA was
isolated for qRT-PCR. (a) relative expression of IL-12 p35 mRNA levels upon BCG stimulation compared to unstimulated control. Bars are median
values, ‡ p = 0.3, n = 6 independent experiments; (b) relative expression of IL-12 p40 mRNA levels upon BCG stimulation compared to
unstimulated control, in the presence or absence of a TLR2 blocking antibody. Bars are median values, * p<0.05 compared to BCG stimulation
with isotype control antibody pre-incubation, n = 6 independent experiments.
doi:10.1371/journal.pone.0162148.g001
Fig 2. Optimization of interleukin (IL)-12 p35 and p40mRNA expression in human neonatal monocyte-derived dendritic cells (mdDCs).
Neonatal mdDCs were primed with recombinant (r) interferon-β (IFN-β) (Type I IFN), and rIFN-γ (Type II IFN) for 12 hours prior to stimulating them
with a synthetic TLR2 agonist, Pam3CSK4. The combination of Pam3CSK4, rIFN-β, and rIFN-γ induced the maximal levels of (a) interleukin (IL)-
12 p35 mRNA and (b) IL-12 p40 mRNA expression in human neonatal monocyte-derived dendritic cells (mdDCs). * p<0.05 compared to
unstimulated control. Data points represent individual donors, the number of individual donors for each condition is shown in the figure, and bars
are mean values.
doi:10.1371/journal.pone.0162148.g002
BCG Vaccine Induction of IL-12 in Neonates
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The BCG vaccine contains extracellular mycobacterial (BCG) DNA
which can induce IFN-α production in human neonatal pDCs
pDCs are the predominant cellular source of secreted Type I IFN (IFN-α) [26]. We found that
BCG bacilli did not stimulate IFN-α production from human neonatal pDCs (data not shown).
However, using PCR for 2 genes used to identify BCG (rpoB and the RD8 portion in BCG)
[25], we found that there was extracellular mycobacterial (BCG) DNA in the cell-free superna-
tants of reconstituted BCG vaccine vials (Fig 3A). BCG DNA stimulation induced modest
upregulation of IFN-α1&2 mRNA production in isolated human umbilical cord pDCs at 8
hours (Fig 3B & 3C). Time points at 8, 16, and 24 hours were examined, and the greatest upre-
gulation was seen at 8 hours. IFN-α is the secreted form of Type I IFN from pDCs [26], and
IFN-α and IFN-β are both Type I IFNs that signal through the Type I IFN receptor [27].
BCG bacilli stimulate human neonatal CD16lo NK cells to produce IFN-γ
in a TLR2-dependent manner
NK cells are a source of early IFN-γ production, and they express TLR2 [28]. Isolated human
umbilical cord NK cells were stimulated with BCG and intracellularly stained for IFN-γ
Fig 3. The Bacille Calmette Guérin (BCG) vaccine contains extracellular mycobacterial (BCG) DNA which induces Type I interferon (IFN)
production in human neonatal plasmacytoid dendritic cells (pDCs). (a) The cell-free supernatants of reconstituted BCG vaccine vials from two
different manufacturers contain BCGDNA. PCR for 2 mycobacterial (BCG-specific) genes on the cell-free supernatants was performed as
described in the Methods section, and the PCR products were run on an agarose gel and stained with ethidium bromide. Isolated human umbilical
cord blood pDCs were stimulated with BCGDNA (100 μg/ml) for 8 hours and the relative expression levels of (b) IFN-α1 mRNA and (c) IFN-α2
mRNA were determined by qRT-PCR. †† p = 0.07, n = 3 independent experiments, bars are median values and error bars are S.D.
doi:10.1371/journal.pone.0162148.g003
BCG Vaccine Induction of IL-12 in Neonates
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production. BCG stimulation induced IFN-γ production from CD16lo NK cells. NK cells pre-
incubated with an anti-TLR2 antibody showed diminished IFN-γ production compared to IgG
isotype control (Fig 4).
Fig 4. BCG stimulates CD16lo natural killer (NK) cells to produce interferon (IFN)-γ in a TLR2-dependent manner.Human neonatal NK cells were
isolated from umbilical cord blood, stimulated with Bacille Calmette Guérin (BCG) overnight (in the presence of Brefeldin-A for the last 4 hours), stained
with a vital dye (L/D Aqua), and intracellularly stained for CD3, CD16, CD56, and interferon (IFN)-γ for flow cytometry analysis. In Fig 4a-e, one
representative experiment is shown. (a) gating strategy, (b) unstimulated control, (c) BCG stimulated, (d) BCG stimulated and pre-incubated with an
isotype control antibody, (e) BCG stimulated and pre-incubated with a Toll-like receptor (TLR)2 blocking antibody. (f) Summary data for n = 5 independent
experiments. Bars are mean values and error bars are S.D. † p = 0.06, BCG+TLR2 blocking IgG vs. BCG+isotype control IgG.
doi:10.1371/journal.pone.0162148.g004
BCG Vaccine Induction of IL-12 in Neonates
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Discussion
The BCG vaccine is unique in its ability to induce Th1-polarized immune responses during the
neonatal period. We propose that the BCG vaccine induces Th1 polarization in neonates by
producing adult-like levels of IL-12 p35 and p40 (IL-12 p70) from cDCs, the predominant
source of IL-12. BCG bacilli could activate TLR2 signaling in cDCs and CD16lo NK cells driv-
ing IL-12 p40 gene expression and IFN-γ secretion, respectively. Extracellular mycobacterial
DNA in the BCG vaccine also could activate TLR9 signaling in pDCs driving IFN-α secretion.
The combination of direct TLR2 activation on cDCs, TLR9-mediated IFN-α secretion by
pDCs, and TLR2-mediated IFN-γ secretion by CD16lo NK cells, could act in concert to pro-
duce adult-like levels of IL-12 p35 and p40 mRNAs in the neonatal mdDCs. The adult-like lev-
els of IL-12 p70 (IL-12 p35 and p40) from the cDCs then would drive Th1 differentiation of
naïve CD4+ T-cells. An illustrative model is shown in Fig 5.
The mycobacterial cell wall contains numerous lipoproteins and glycolipoproteins that act
as potent TLR2/1 and TLR2/6 ligands [29–34]. The predominant role of TLR2 activation and
signaling that we observed in BCG-induced IL-12 p40 production from human neonatal
mdDCs is consistent with a previous publication utilizing TLR2 knockout mice [35]. Unlike
another study using TLR4 knockout mice [36], we found that blocking TLR4 did not have an
additive effect on the TLR2 blocking for BCG-stimulated IL-12 p40 production in human neo-
natal mdDCs. Given the predominant effect of TLR2 blockade, it would have been difficult to
observe an additional effect of TLR4 blockade. Human neonatal mdDCs have repressed IL-12
p35 gene expression compared to adult cells [22]. Although TLR2 stimulation by itself (NF-κB
activation only) was sufficient to upregulate IL-12 p40 mRNA a little, it was not sufficient to
upregulate IL-12 p35 mRNA production in human neonatal mdDCs. TLR2 stimulation + Type
II IFN could upregulate IL-12 p35 mRNA in neonatal mdDCs to a degree, but the combination
of TLR2 stimulation + Type I IFN + Type II IFN achieved the maximal upregulation of IL-12
Fig 5. Illustrative model demonstrating how the Bacille Calmette Guérin (BCG) vaccine might drive interleukin (IL)-12 p35 and p40 (IL-12
p70) production and CD4+ T-cell T-helper 1 (Th1) polarization in neonates. IFN = interferon; cDC = conventional dendritic cell; NK = natural
killer; pDC = plasmacytoid dendritic cell; TLR = Toll-like receptor.
doi:10.1371/journal.pone.0162148.g005
BCG Vaccine Induction of IL-12 in Neonates
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p35 and p40 mRNAs. In the cord blood (neonatal) mdDC preparations, the vast majority of
the non-mdDCs were undifferentiated monocytes (approximately 25–30%). Although mdDCs
are a primary source of IL-12, we cannot exclude the possibility that monocyte-derived IL-12
p35 and p40 production contributed to our findings. IL-12 p70 protein levels were also not
examined in these experiments, as the upregulation solely of IL-12 p40 would manifest as
increased IL-12 p70 levels. The absence of IL-12 p35 and p40 protein measurements is a poten-
tial limitation of this study.
pDCs are the predominant cellular source of secreted Type I IFN (IFN-α) largely through
TLR7/9 activation [26]. Mycobacterial DNA is a well-recognized potent TLR9 activating ligand
[37]. We found that the cell-free supernatants of reconstituted BCG vaccine vials from 2 differ-
ent manufacturers contained naked extracellular BCG DNA, and BCG DNA could stimulate
IFN-α production from human neonatal pDCs (likely through TLR9 activation). The naked
extracellular mycobacterial DNA in BCG vaccine vials is likely the result of dead and lysed
BCG bacilli from the BCG vaccine manufacturing process. It should be noted that quality con-
trol standards established by the World Health Organization (WHO) for BCG vaccine prod-
ucts do not assess the presence of mycobacterial DNA in reconstituted vaccines [38]. The
presence of extracellular mycobacterial DNA in reconstituted BCG vaccine vials likely serves as
a TLR9 adjuvant, and an in vivo stimulus of local neonatal pDC Type I IFN production when
the vaccine is given at birth. Mycobacterial DNA in the intact BCG bacilli might also contribute
to TLR9-mediated neonatal pDC IFN-α production. However, we also observed that intact
BCG bacilli did not stimulate IFN-α production from human neonatal pDCs. It is likely that
the DNA in intact BCG bacilli cannot efficiently access TLR9 (in an endosomal location) in the
pDCs. In addition to its effects on IL-12 p35 and p40 upregulation in neonates, Type I IFN can
polarize neonatal CD4+ T-cells to a Th1 phenotype in an IL-12 independent manner [39].
Type I IFN can also induce IFN-γ production from neonatal NK cells [40].
Finally, NK cells are a source of early IFN-γ (Type II IFN) production and express TLR2
[41, 42]. CBMCs have a lower percentage of CD56+ NK cells compared to adult peripheral
blood mononuclear cells (PBMCs) [43]. Confirming a previous study by Watkins et al.[44], we
found that BCG bacilli could stimulate neonatal NK cells to produce IFN-γ. We further dem-
onstrated that BCG bacilli induce IFN-γ production specifically from the CD16lo subset of
human neonatal NK cells in a TLR2-dependent manner. The purity of the neonatal NK cell
preparation (>95%) and the TLR2-dependence suggest that BCG bacilli are directly stimulat-
ing IFN-γ production in the CD16lo NK cells. However, we cannot exclude the possibility of
some indirect NK cell activation.
Combining the aforementioned data, we have proposed a model where the BCG vaccine
could stimulate a combination of TLRs 2&9 signaling, and Types I and II IFN production,
among neonatal cDCs, pDCs, and CD16lo NK cells. Intact BCG bacilli have TLR2 ligands in
their cell wall, and extracellular BCG DNA in the vaccine vials could act as a pDC TLR9 ligand.
The combination of the signals and cell subsets noted above could act in concert to optimize
neonatal IL-12 p35 and p40 (IL-12 p70) production and subsequent CD4+ T-cell Th1 polariza-
tion in neonates (Fig 5). We postulate that the interaction between neonatal cDCs, pDCs, and
CD16lo NK cells would take place within the dermis and regional draining lymph nodes of the
BCG vaccination site in vivo.
Our data demonstrates the potential mechanism by which the BCG vaccine could stimulate
optimal neonatal IL-12 p35 and p40 (IL-12 p70) production by utilizing multiple innate
immune cells. The production of adult-like levels of IL-12 p70 in neonates would promote the
anti-mycobacterial CD4+ T-cell Th1 polarization that has been seen following neonatal BCG
vaccination, and it could also contribute to beneficial heterologous Th1 immune effects of BCG
vaccination [5, 9–11, 21]. Developing an effective Th1-inducing adjuvant for the neonatal
BCG Vaccine Induction of IL-12 in Neonates
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period would be the first step towards the goal of improving vaccinations against toxins (e.g.
diphtheria/pertussis/tetanus) and viruses (e.g. polioviruses, measles virus) so that they could
begin at birth and require fewer booster doses. Our data suggests that an effective neonatal
Th1-inducing adjuvant should be comprised of a TLR2 agonist, Type I IFN, and Type II IFN.
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